L-4F differentially alters plasma levels of oxidized fatty acids resulting in more anti-inflammatory HDL in mice

Drug Metabolism Letters

Volumn 4, Issue 3, 2010, Pages 139-148

  Imaizumi, Satoshi ^a,b   Grijalva, Victor ^a,b   Navab, Mohamad ^a,b   van Lenten, Brian J ^a,b   Wagner, Alan C ^a,b   Anantharamaiah, G M ^c   Fogelman, Alan M ^a,b   Reddy, Srinivasa T ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Atherosclerosis Research Unit   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Apoa I mimetic peptides; Arachidonic acid metabolism; EET; HETE; HODE; HPODE; L 4F

Indexed keywords

13 HYDROXY OCTADECADIENOIC ACID; 15 HYDROXYICOSATETRAENOIC ACID; 5 HYDROXYICOSATETRAENOIC ACID; 9 HYDROXY OCTADECADIENOIC ACID; APOLIPOPROTEIN A I MIMETIC PEPTIDE 4F; APOLIPOPROTEIN A1; CORIOLIC ACID; CYTOCHROME P450; FATTY ACID; HIGH DENSITY LIPOPROTEIN; LIPID; LIPID BINDING PROTEIN; OXIDIZING AGENT; UNCLASSIFIED DRUG; 13 HYDROPEROXY 9,11 OCTADECADIENOIC ACID; 13-HYDROPEROXY-9,11-OCTADECADIENOIC ACID; 13-HYDROXY-9,11-OCTADECADIENOIC ACID; 14,15 EPOXY 5,8,11 EICOSATRIENOIC ACID; 14,15-EPOXY-5,8,11-EICOSATRIENOIC ACID; 15 HYDROXY 5,8,11,13 ICOSATETRAENOIC ACID; 15-HYDROXY-5,8,11,13-EICOSATETRAENOIC ACID; 5-HYDROXY-6,8,11,14-EICOSATETRAENOIC ACID; 9-HYDROXY-10,12-OCTADECADIENOIC ACID; ANTIINFLAMMATORY AGENT; APOLIPOPROTEIN E; CONJUGATED LINOLEIC ACID; DIHOMO GAMMA LINOLENIC ACID; DIMORPHECOLIC ACID; DRUG DERIVATIVE; HYDROXYICOSATETRAENOIC ACID; L 4F PEPTIDE; L-4F PEPTIDE; LINOLEIC ACID; LIPID PEROXIDE; PEPTIDE;

ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROSIS; BLOOD LEVEL; FATTY ACID BLOOD LEVEL; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; WILD TYPE; ANIMAL; BLOOD; C3H MOUSE; C57BL MOUSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETICS; LIQUID CHROMATOGRAPHY; MOUSE MUTANT; OXIDATION REDUCTION REACTION; SPECIES DIFFERENCE; SUBCUTANEOUS DRUG ADMINISTRATION; TANDEM MASS SPECTROMETRY; TIME; UPREGULATION;

MUS;

8,11,14-EICOSATRIENOIC ACID; ANIMALS; ANTI-INFLAMMATORY AGENTS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CHROMATOGRAPHY, LIQUID; ENZYME-LINKED IMMUNOSORBENT ASSAY; FATTY ACIDS; FEMALE; HYDROXYEICOSATETRAENOIC ACIDS; INJECTIONS, SUBCUTANEOUS; LINOLEIC ACIDS; LINOLEIC ACIDS, CONJUGATED; LIPID PEROXIDES; LIPOPROTEINS, HDL; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, KNOCKOUT; OXIDATION-REDUCTION; PEPTIDES; SPECIES SPECIFICITY; TANDEM MASS SPECTROMETRY; TIME FACTORS; UP-REGULATION;

EID: 78049417783     PISSN: 18723128     EISSN: None     Source Type: Journal    
DOI: 10.2174/187231210791698438     Document Type: Article

References (34)

1. Sigari, F.; Lee, C.; Witztum, J.L. Reaven, P.D. Fibroblasts that over-express 15-lipoxygenase generate bioactive and minimally modi-fied LDL. Arterioscler Thromb. Vasc. Biol., 1997, 17, 3639-3645.
2. Sakashita, T.; Takahashi, Y.; Kinoshita, T.; Yoshimoto, T. Essen-tial involvement of 12-lipoxygenase in regiospecific and stereo-specific oxidation of low density lipoprotein by macrophages. Eur.J. Biochem., 1999, 265, 825-831.
3. Parthasarathy, S.; Litvinov, D.; Selvarajan, K.; Garelnabi, M. Lipidperoxidation and decomposition-conflicting roles in plaque vulnerability and stability. Biochim. Biophys. Acta., 2008, 1781, 221-231.
4. Navab, M.; Hama, S.Y.; Cooke, C.J.; Anantharamaiah, G.M.; Chaddha, M.; Jin, L.; Subbanagounder, G.; Faull, K.F.; Reddy, S.T.; Miller, N.E.; Fogelman, A.M. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized lowdensity lipoprotein: step 1. J. Lipid Res., 2000, 41, 1481-1494.
5. Navab, M.; Hama, S.Y.; Anantharamaiah, G.M.; Hassan, K.; Hough, G.P.; Watson, A. D.; Reddy, S.T.; Sevanian, A.; Fonarow, G.C.; Fogelman, A.M. Normal high density lipoprotein inhibitsthree steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J. Lipid Res., 2000, 41, 1495-1508.
6. Folick, V.A.; Nivar-Aristy, R.A.; Krajewski, L.P.; Cathcart, M.K. Lipoxygenase contributes to the oxidation of lipids in human atherosclerotic plaques. J. Clin. Invest., 1995, 96, 504-510.
7. Funk, C.D.; Cyrus, T. 12/15-lipoxygenase, oxidative modificationof LDL and atherogenesis. Trends Cardiovasc. Med., 2001, 11,116-124.
8. Kuhn, H.; Belkner, J.; Zaiss, S.; Fahrenklemper, T.; Wohlfeil, S. Involvement of 15-lipoxygenase in early stages of atherogenesis. J.Exp. Med., 1994, 179, 1903-1911.
9. Cyrus, T.; Witztum, J.L.; Rader, D.J.; Tangirala, R.; Fazio, S.; Linton, M.F.; Funk, C.D. Disruption of the 12/15-lipoxygenasegene diminishes atherosclerosis in apo E-deficient mice. J. Clin.Invest., 1999, 103, 1597-1604.
10. George, J.; Afek, A.; Shaish, A.; Levkovitz, H.; Bloom, N.; Cyrus, T.; Zhao, L.; Funk, C.D.; Sigal, E.; Harats, D. 12/15-Lipoxygenasegene disruption attenuates atherogenesis in LDL receptor-deficientmice. Circulation, 2001, 104, 1646-1650.
11. Patricia, M.K.; Kim, J.A.; Harper, C.M.; Shih, P.T.; Berliner, J.A.; Natarajan, R.; Nadler, J.L.; Hedrick, C.C. Lipoxygenase productsincrease monocyte adhesion to human aortic endothelial cells. Ar-terioscler. Thromb. Vasc. Biol., 1999, 19, 2615-2622.
12. Mallat, Z.; Nakamura, T.; Ohan, J.; Leseche, G.; Tedgui, A.; Ma-clouf, J.; Murphy, R.C. The relationship of hydroxyeicosatetraenoicacids and F2-isoprostanes to plaque instability in human carotidatherosclerosis. J. Clin. Invest., 1999, 103, 421-427.
13. Shishehbor, M.H.; Zhang, R.; Medina, H.; Brennan, M.L.; Bren-nan, D.M.; Ellis, S.G.; Topol, E.J.; Hazen, S.L. Systemic elevationsof free radical oxidation products of arachidonic acid are associatedwith angiographic evidence of coronary artery disease. FreeRadic.Biol. Med., 2006, 41, 1678-1683.
14. Sarkis, A.; Lopez, B.; Roman, R.J. Role of 20-hydroxyei-cosatetraenoic acid and epoxyeicosatrienoic acids in hypertension.Curr. Opin. Nephrol. Hypertens, 2004, 13, 205-214.
15. Spector, A. Arachidonic acid cytochrome P450 epoxygenase path-way. J. Lipid Res., 2009, 50, S52-S56.
16. Navab, M.; Anantharamaiah, G.M.; Reddy, S.T.; Fogelman, A.M. Apolipoprotein A-I mimetic peptides and their role in atherosclero-sis prevention. Nat. Clin. Pract. Cardiovasc. Med., 2006, 3, 540-547.
17. Van Lenten, B.J.; Wagner, A.C.; Jung, C.L.; Ruchala, P.; Waring, A.J., Lehrer, R.I.; Watson, A.D.; Hama, S.; Navab, M.; Anan-tharamaiah, G.M.; Fogelman, A.M. Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinitythan human apoA-I. J. Lipid Res., 2008, 49, 2302-2311.
18. Navab, M.; Anantharamaiah, G.M.; Hama, S.; Garber, D.W.; Chaddha, M.; Hough, G.; Lallone, R.; Fogelman, A.M. Oral ad-ministration of an Apo A-I mimetic Peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation, 2002, 105, 290-292.
19. Peterson, S.J.; Drummond, G.; Kim, D.H.; Li, M.; Kruger, A.L.; Ikehara, S.; Abraham, N.G. L-4F treatment reduces adiposity, in-creases adiponectin levels, and improves insulin sensitivity inobese mice. J. Lipid Res., 2008, 49, 1658-1669.
20. Folch, J.; Lees, M.; Sloane Stanley, G.H. A simple method for theisolation and purification of total lipides from animal tissues. J.Biol. Chem., 1957, 226, 497-509.
21. Bligh, E.G.; Dyer, W.J. A rapid method of total lipid extraction andpurification. Can. J. Biochem. Physiol., 1959, 37, 911-917.
22. Navab, M.; Hama, S.Y.; Hough, G.P.; Subbanagounder, G.; Reddy, S.T.; Fogelman, A.M. A cell-free assay for detecting HDL that isdysfunctional in preventing the formation of or inactivating oxi-dized phospholipids. J. Lipid Res., 2001, 42, 1308-1317.
23. Van Lenten, B.J.; Wagner, A.C.; Navab, M.; Anantharamaiah, G.M.; Hama, S.; Reddy, S.T.; Fogelman, A.M. Lipoprotein in-flammatory properties and serum amyloid A levels but not choles-terol levels predict lesion area in cholesterol-fed rabbits. J. LipidRes., 2007, 48, 2344-2353.
24. Watanabe, J.; Chou, K.J.; Liao, J.C.; Miao, Y.; Meng, H-H.; Ge, H.; Grijalva, V.; Hama, S.; Kozak, K.; Buga, G.; Whitelegge, J.P.; Lee, T.D.; Faris-Eisner, R.; Navab, M.; Fogelman, A.M.; Reddy, S.T. Differential association of hemoglobin with proinflammatoryhigh density lipoproteins in atherogenic/hyperlipidemic mice. Anovel biomarker of atherosclerosis. J. Biol. Chem., 2007, 282,23698-23707.
25. Cruz, D.; Watson, A.D.; Miller, C.S.; Montoya, D.; Ochoa, M-T.; Sieling, P.A.; Gutierrez, M.A.; Navab, M.; Reddy, S.T. Witztum, J.L.; Fogelman, A.M.; Rea, T.H.; Eisenberg, D.; Berliner, J.; Mod-lin, R.L. Host-derived oxidized phospholipids and HDL regulateinnate immunity in human leprosy. J. Clin. Invest., 2008, 118,2917-2928.
26. Forte, T.M.; Subbanagounder, G.; Berliner, J.A.; Blanche, P.J.; Clermont, A.O.; Jia, Z.; Oda, M.N.; Krauss R.M.; Bielicki, J.K. Al-tered activities of anti-atherogenic enzymes LCAT, paraoxonase,and platelet-activating factor acetylhydrolase in atherosclerosis-susceptible mice. J. Lipid Res., 2002, 43, 477-485.
27. Buga, G.M.; Frank, J.S.; Mottino, G.A.; Hakhamian, A.; Nara-simha, A.; Watson, A.D.; Yekta, B.; Navab, M.; Reddy, S.T., An-antharamaiah, G.M.; Fogelman, A.M. D-4F reduces EO6 immunoreactivity, SREBP-1c mRNA levels, and renal inflammationin LDL receptor-null mice fed a Western diet. J. Lipid Res., 2008,49, 192-205.
28. Navab, M.; Shechter, I.; Anantharamaiah, G.M.; Reddy, S.T.; VanLenten, B.J.; Fogelman, A.M. Structure and function of HDL mimetics. Arterioscler Thromb. Vasc. Biol., 2010, 30, 164-168.
29. Sacerdoti, D.; Colombrita, C.; Di Pascoli, M.; Schwartzman, M.L.; Bolognesi, M.; Falck, J.R.; Gatta, A.; Abraham, N.G. 11,12-epoxyeicosatrienoic acid stimulates heme oxygenase-1 in endothelial cells. Prostaglandins Other Lipid Mediat., 2007, 82, 155-161.
30. Sodhi, K.; Inoue, K.; Gotlinger, K.H.; Canestraro, M.; Vanella, L.; Kim, D.H.; Manthati, V.L.; Koduru, S.R.; Falck, J.R.; Schwartzman, M.L.; Abraham, N.G. Epoxyeicosatrienoic acid agonist rescues the metabolic syndrome phenotype of HO-2 null mice. J.Pharmacol. Exp. Ther., 2009, 331, 906-916.
31. Kruger, A.L.; Peterson, S.; Turkseven, S.; Kaminski, P.M.; Zhang, F.F.; Quan, S.; Wolin, M.S.; Abraham, N.G. D-4F induces hemeoxygenase-1 and extracellular superoxide dismutase, decreases endothelial cell sloughing, and improves vascular reactivity in ratmodel of diabetes. Circulation, 2005, 111, 3126-3134.
32. Peterson, S.J.; Husney, D.; Kruger, A.L.; Olszanecki, R.; Ricci, F.; Rodella, L.F.; Stacchiotti, A.; Rezzani, R.; McClung, J.A.; Aro-now, W.S.; Ikehara, S.; Abraham, N.G. Long-term treatment withthe apolipoprotein A1 mimetic peptide increases antioxidants andvascular repair in type I diabetic rats. J Pharmacol. Exp. Ther.,2007, 322. 514-520.
33. Peterson, S.J.; Drummond, G.; Kim, D.H.; Li, M.; Kruger, A.L.; Ikehara, S.; Abraham, N.G. L-4F treatment reduces adiposity, in-creases adiponectin levels, and improves insulin sensitivity inobese mice. J. Lipid Res., 2008, 49, 1658-1669.
34. Peterson, S.J; Kim, D.H.; Li, M.; Positano, V.; Vanella, L.; Rod-ella, L.F.; Piccolomini, F.; Puri, N.; Gastaldelli, A.; Kusmic, C.;L'Abbate, A.; Abraham, N.G. The L-4F mimetic peptide preventsinsulin resistance through increased levels of HO-1, pAMPK, andpAKT in obese mice. J. Lipid Res., 2009, 50, 1293-1304.